# COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

> **NCT04852978** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 295 (actual)

## Conditions studied

- Healthy
- Chronic Stable Illness

## Interventions

- **DRUG:** casirivimab+imdevimab
- **BIOLOGICAL:** Moderna mRNA-1273 vaccine

## Key facts

- **NCT ID:** NCT04852978
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-29
- **Primary completion:** 2022-11-21
- **Final completion:** 2022-11-21
- **Target enrollment:** 295 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04852978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04852978, "COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04852978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*